Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis

Andreas Kerschbaumer,Josef S Smolen,Ricardo J O Ferreira,Heidi Bertheussen,Xenofon Baraliakos,Daniel Aletaha,Dennis G McGonagle,Désirée van der Heijde,Iain B McInnes,Bente Appel Esbensen,Kevin L Winthrop,Wolf-Henning Boehncke,Jan W Schoones,Laure Gossec

DOI: https://doi.org/10.1136/ard-2024-225534

IF: 27.973

2024-03-19

Annals of the Rheumatic Diseases

Abstract:Objectives To obtain an overview of recent evidence on efficacy and safety of pharmacological treatments in psoriatic arthritis (PsA). Methods This systematic literature research (SLR) investigated the efficacy and safety of conventional synthetic (cs), biological (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) in patients with PsA. A systematic database search using Medline, EMBASE, Cochrane CENTRAL was conducted to identify relevant articles published since the previous update in 2019 until 28 December 2022. Efficacy was assessed in trials while for safety observational data were also considered. Adverse events of special interest were infections (including herpes zoster, influenza and tuberculosis), malignancies, major adverse cardiovascular events, venous thromboembolisms, liver disease, laboratory changes and psychiatric adverse events. No meta-analyses were performed. Results For efficacy, of 3946 articles screened, 38 articles (30 trials) were analysed. The compounds investigated included csDMARDs (leflunomide, methotrexate), bDMARDs inhibiting IL17 (bimekizumab, brodalumab, ixekizumab, izokibep, secukinumab,), IL-23 (guselkumab, risankizumab, tildrakizumab), IL-12/23 (ustekinumab) as well as TNF (adalimumab, certolizumab-pegol, etanercept, infliximab, golimumab) and Janus Kinase inhibitors (JAKi) (brepocitinib, deucravacitinib, tofacitinib, upadacitinib). The compounds investigated were efficacious in improving signs and symptoms of PsA, improving physical functioning and quality of life. For safety, 2055 abstracts were screened, and 24 articles analysed: 15 observational studies and 9 long-term follow-ups of trials, assessing glucocorticoids, TNFi, IL-17i, JAKi, IL-12/23i and PDE4i (apremilast). Safety indicators were generally coherent with the previous SLR in 2019. Conclusion The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA.

rheumatology

What problem does this paper attempt to address?

This paper aims to address the effectiveness and safety issues of drug treatment for psoriatic arthritis (PsA). Specifically, the study investigated the efficacy and safety of conventional synthetic (cs), biological (b), and targeted - synthetic (ts) disease - modifying antirheumatic drugs (DMARDs) in PsA patients through the systematic literature review (SLR) method. The drugs of interest include various inhibitors, such as biologics that inhibit IL - 17, IL - 23, IL - 12/23, and TNF, as well as Janus kinase inhibitors (JAKi), etc.

### Research Background
Psoriatic arthritis is a chronic inflammatory disease, commonly seen in psoriasis patients, mainly manifested as pauci - or poly - arthritis, enthesitis, and dactylitis. If left untreated, it may lead to radiological damage and even potential joint destruction. In recent years, significant progress has been made in drug treatment for PsA, but there is still a lack of reviews on the effectiveness and safety of these drugs in systematic treatment.

### Research Objectives
1. **Obtain recent evidence**: Systematically review relevant literature published since 2019 to evaluate the effectiveness and safety of different DMARDs in PsA patients.
2. **Update guidelines**: Provide the latest evidence support for the 2023 European League Against Rheumatism (EULAR) to update PsA management recommendations.

### Main Research Contents
- **Effectiveness**: 3,946 articles were analyzed, and finally 38 articles (30 trials) were included. The drugs involved include csDMARDs (such as leflunomide, methotrexate), bDMARDs (such as bimekizumab, brodalumab, ixekizumab, isokibep, secukinumab that inhibit IL - 17, guselkumab, risankizumab, tildrakizumab that inhibit IL - 23, ustekinumab that inhibits IL - 12/23, and adalimumab, certolizumab, etanercept, infliximab, golimumab that inhibit TNF), and tsDMARDs (such as brepocitinib, decernotinib, tofacitinib, upadacitinib). The study found that these drugs are effective in improving the symptoms of PsA, enhancing physical function, and quality of life.
- **Safety**: 2,055 abstracts were screened, and finally 24 articles (15 observational studies and 9 long - term follow - up trials) were included to evaluate the safety of glucocorticoids, TNFi, IL - 17i, JAKi, IL - 12/23i, and PDE4i (apremilast). The adverse events of particular focus include infections (such as herpes zoster, influenza, tuberculosis), malignancies, major cardiovascular adverse events, venous thromboembolism, liver diseases, changes in laboratory indicators, and psychiatric adverse events. The safety indicators are generally consistent with the results of the 2019 SLR.

### Conclusion
This systematic literature review provides the latest evidence for the 2023 EULAR PsA Management Recommendations Task Force, covering relevant literature published since 2019. The research results not only update the effectiveness and safety of known drugs but also introduce the latest progress of new biological DMARDs and JAK inhibitors, providing an important reference for clinical practice.